PMV Pharmaceuticals, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
PMV Pharmaceuticals completed enrollment of platinum-resistant/refractory ovarian cancer patients in the PYNNACLE Phase 2 monotherapy trial for rezatapopt (PC14586), a p53 Y220C reactivator. The company plans to submit an NDA for accelerated approval in Q1 2027. Cash position declined to $79.4M (June 30, 2026) from $112.9M (Dec 31, 2025), providing runway through Q2 2027; operating cash burn for H1 2026 was $34.3M.
Why this rating
Clinical milestone completion + near-term regulatory pathway are meaningful for a $53M-cap biotech; cash runway 9 months provides execution window but burn rate material to asset base.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.